Literature DB >> 12848947

Proinsulin-a pathogenic autoantigen in type 1 diabetes.

Parth Narendran1, Stuart I Mannering, Leonard C Harrison.   

Abstract

Type 1 diabetes (T1D) is an autoimmune disease characterised by immunity to pancreatic beta-cell autoantigens, associated with beta-cell destruction leading to insulin deficiency and hyperglycaemia. The rigorous definition of an autoimmune disease requires evidence that an autoantigen elicits pathological immune responses. Using criteria for the pathogenicity of an autoantigen, we examine the evidence for proinsulin as an autoantigen in T1D. We conclude that proinsulin satisfies these criteria. As a corollary, proinsulin is a potential immunotherapeutic tool for the prevention of T1D.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12848947     DOI: 10.1016/s1568-9972(03)00009-0

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  26 in total

1.  Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice.

Authors:  Tatiana Takiishi; Hannelie Korf; Tom L Van Belle; Sofie Robert; Fabio A Grieco; Silvia Caluwaerts; Letizia Galleri; Isabella Spagnuolo; Lothar Steidler; Karolien Van Huynegem; Pieter Demetter; Clive Wasserfall; Mark A Atkinson; Francesco Dotta; Pieter Rottiers; Conny Gysemans; Chantal Mathieu
Journal:  J Clin Invest       Date:  2012-04-09       Impact factor: 14.808

2.  Priming and effector dependence on insulin B:9-23 peptide in NOD islet autoimmunity.

Authors:  Maki Nakayama; Joshua N Beilke; Jean M Jasinski; Masakazu Kobayashi; Dongmei Miao; Marcella Li; Marilyne G Coulombe; Edwin Liu; John F Elliott; Ronald G Gill; George S Eisenbarth
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

3.  Immunotherapy after recent-onset type 1 diabetes: combinatorial treatment for achieving long-term remission in humans?

Authors:  Damien Bresson; Matthias von Herrath
Journal:  Rev Diabet Stud       Date:  2004-11-10

Review 4.  Pathogenic mechanisms in type 1 diabetes: the islet is both target and driver of disease.

Authors:  Kate L Graham; Robyn M Sutherland; Stuart I Mannering; Yuxing Zhao; Jonathan Chee; Balasubramanian Krishnamurthy; Helen E Thomas; Andrew M Lew; Thomas W H Kay
Journal:  Rev Diabet Stud       Date:  2012-12-28

Review 5.  Deciphering the Pathogenesis of Human Type 1 Diabetes (T1D) by Interrogating T Cells from the "Scene of the Crime".

Authors:  Sally C Kent; Stuart I Mannering; Aaron W Michels; Jenny Aurielle B Babon
Journal:  Curr Diab Rep       Date:  2017-09-02       Impact factor: 4.810

6.  The A-chain of insulin is a hot-spot for CD4+ T cell epitopes in human type 1 diabetes.

Authors:  S I Mannering; S H Pang; N A Williamson; G Naselli; E C Reynolds; N M O'Brien-Simpson; A W Purcell; L C Harrison
Journal:  Clin Exp Immunol       Date:  2009-03-09       Impact factor: 4.330

Review 7.  Trials in type 1 diabetes: Antigen-specific therapies.

Authors:  Ken T Coppieters; Leonard C Harrison; Matthias G von Herrath
Journal:  Clin Immunol       Date:  2013-02-15       Impact factor: 3.969

8.  Transfer of hematopoietic stem cells encoding autoantigen prevents autoimmune diabetes.

Authors:  Raymond J Steptoe; Janine M Ritchie; Leonard C Harrison
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

9.  Mucosal tolerance to prevent type 1 diabetes: can the outcome be improved in humans?

Authors:  Arno Hanninen; Leonard C Harrison
Journal:  Rev Diabet Stud       Date:  2004-11-10

10.  Dendritic cell-based assays, but not mannosylation of antigen, improves detection of T-cell responses to proinsulin in type 1 diabetes.

Authors:  Parth Narendran; Kathryn Elsegood; Nicola J Leech; Wallace M Macindoe; Geert-Jan Boons; Colin M Dayan
Journal:  Immunology       Date:  2004-04       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.